Monday, January 07, 2013 8:03:41 AM
08:02 AM ImmunoCellular Therapeutics (IMUC) provides an update about the various cancer vaccines it's developing, saying it expects the Data Safety Monitoring Committee to conduct an interim safety and futility analysis of the Phase IIb trial of ICT-107, which targets glioblastoma antigens and cancer stem cells, early this year. (PR)
Recent IMUC News
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 08/02/2023 07:11:57 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM